| Revision as of 12:55, 3 January 2007 editAgjchs (talk | contribs)104 editsm corrected my previous edit← Previous edit | Revision as of 14:03, 3 January 2007 edit undoJmax- (talk | contribs)910 editsm Reverted edits by Agjchs to last version by JniNext edit → | ||
| Line 11: | Line 11: | ||
| Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression. | Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression. | ||
| == External link == | |||
| * free PDF containing comprehensive charts | |||
| {{Antidepressants}} | {{Antidepressants}} | ||
| ] | ] | ||
| ] | ] | ||
Revision as of 14:03, 3 January 2007
Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the CNS by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal via the norepinephrine transporter. Virtually, they do not act at other monoamine transporters.
List of NRIs
- Atomoxetine (Strattera)
- Reboxetine (Edronax)
- Viloxazine (Vivalan)
- Maprotiline (Ludiomil)
Strattera is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Off-label uses include the treatment of depression and anxiety.
Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |